1-(Phenylamino)-2-pyrrolidone | 6837-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(Phenylamino)-2-pyrrolidone
• 英文别名: 1-Phenylamino-pyrrolidin-2-on；1-anilino-pyrrolidin-2-one；N-phenylamino-2-pyrrolidone；1-anilinopyrrolidin-2-one
• CAS: 6837-16-7
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: OJHITUPLBOBLHT-UHFFFAOYSA-N

物化性质

• 熔点：
  154-155 °C
• 沸点：
  281.3±23.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(Phenylamino)-2-pyrrolidone 在 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 以54%的产率得到3-(2-氨基乙基)吲哚-2-酮盐酸盐
  参考文献：
  名称：

  Heterocylization ofN-phenylamino-2-pyrrolidones

  摘要：

  DOI：

  10.1007/bf01373543
• 作为产物：
  描述：

  formaldehyde phenylhydrazone 在 溶剂黄146 、 锌 作用下， 以 xylene 为溶剂， 反应 25.5h， 生成 1-(Phenylamino)-2-pyrrolidone
  参考文献：
  名称：

  的迈克尔加成反应可形成碳-碳键

  摘要：

  叔丁基hydr和三苯甲基-的锂盐与巴豆酸甲酯反应形成C捕获的偶氮酯，并且通过醛叔丁基hydr与丙烯酸甲酯或丙烯腈的热烯反应，以及醛苯hydr与丙烯的热烯反应观察到类似的产物。丙烯酸甲酯 这些产品可以分为合成有用的γ-酮酯，γ-酮腈，饱和酯，γ-烷基-2-吡咯烷酮和γ-氨基酯。

  DOI：

  10.1039/c39840001095

文献信息

• [EN] HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES CONVENANT COMME COMPOSÉS SE LIANT AUX INHIBITEURS DE PROTÉINES D'APOPTOSE
  申请人：NUEVOLUTION AS

  公开号：WO2009152824A1

  公开（公告）日：2009-12-23

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis in proliferating cells, and for sensitizing cells to inducers of apoptosis. The present invention furthermore provides a polymeric compound of formulas (VI) or (VII), comprising either at least two monomeric units of compounds of formula (I), or at least one monomeric unit of a compound of formula (I) and an entity E. The present invention further relates to pharmaceutical compositions comprising said compounds of formulas (I), (VI), and (VII) and the use of said compounds in medicine.

  本发明涉及式(I)的化合物，或其药学上可接受的盐、溶剂化合物，这些化合物与凋亡抑制蛋白(IAPs)结合。本发明的化合物可用作诊断和治疗剂，用于治疗增殖性疾病，如癌症，促进增殖细胞中的凋亡，并使细胞对凋亡诱导剂敏感。本发明还提供了具有式(VI)或(VII)的聚合物化合物，包括至少两个式(I)化合物的单体单位，或至少一个式(I)化合物的单体单位和实体E。本发明还涉及包含所述式(I)、(VI)和(VII)化合物的药物组合物以及在医学中使用所述化合物的用途。
• IAP BINDING COMPOUNDS
  申请人：Lundorf Mikkel Dybro

  公开号：US20110230419A1

  公开（公告）日：2011-09-22

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis in proliferating cells, and for sensitizing cells to inducers of apoptosis. The present invention furthermore provides a polymeric compound of formulas (VI) or (VII), comprising either at least two monomeric units of compounds of formula (I), or at least one monomeric unit of a compound of formula (I) and an entity E. The present invention further relates to pharmaceutical compositions comprising said compounds of formulas (I), (VI), and (VII) and the use of said compounds in medicine.

  本发明涉及式(I)的化合物，或其药学上可接受的盐、溶剂化合物或前药，其与凋亡抑制蛋白（IAPs）结合。本发明的化合物可用作诊断和治疗增生性疾病，例如癌症，促进增殖细胞的凋亡，并使细胞对凋亡诱导剂敏感。本发明还提供式(VI)或(VII)的聚合物化合物，其中包括至少两个式(I)的单体单位，或至少一个式(I)的单体单位和一个实体E。本发明还涉及包含上述化合物的药物组合物，以及在医学中使用上述化合物的用途。
• Lactams as inhibitors of rock
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10112929B2

  公开（公告）日：2018-10-30

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)化合物：或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• Preparation of N-arylamino-2-pyrrolidones from arylhydrazides of ?-chlorobutyric acid
  作者：A. V. Blokhina、V. G. Boronin、V. V. Druzhinina、V. P. Zhestkov、Yu. N. Portnov

  DOI：10.1007/bf00546732

  日期：1987.4
• Facile synthesis of bicyclic 1-arylpyrazol-5-ones
  作者：Yanjun Wu、Kunrui Wang、Zhuo Li、Xu Bai、Ning Xi

  DOI：10.1016/j.tetlet.2013.10.139

  日期：2014.1

  In this Letter, we described a facile method for constructing fused bicyclic 1-arylpyrazol-5-one ring system. We employed various methylene-containing carboxylic acids as the substrates and proved that the pyrazolone ring closure requires activated methylene group in intermediate II. Accordingly, a series of structurally diversified, fused bicyclic 1-arylpyrazol-5-ones was prepared in moderate to high yields using the requisite substrates. (C) 2013 Elsevier Ltd. All rights reserved.